A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment-Naive Patients With Relapsing-Remitting Multiple Sclerosis

Trial Profile

A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment-Naive Patients With Relapsing-Remitting Multiple Sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Alemtuzumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CARE-MS-I
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 19 Jun 2018 Results (NCT00530348, NCT00548405 and NCT00930553) examining the association between lymphocyte repopulation patterns and clinical/MRI disease activity through 6 years presented at the 4th Congress of the European Academy of Neurology
    • 19 Jun 2018 Results presenting efficacy/safety outcomes over 7 years (2 years core study plus 4 years extension and TOPAZ Y1) in alemtuzumab-treated patients from CARE-MS presented at the 4th Congress of the European Academy of Neurology
    • 19 Jun 2018 Results presenting MRI lesion/BVL outcomes over 7 y (2 y core study plus 4 y extension, and TOPAZ Y1) in alemtuzumab-treated CARE-MS I patients presented at the 4th Congress of the European Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top